• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应对非酒精性脂肪性肝炎流行:行动呼吁。

Preparing for the NASH epidemic: A call to action.

作者信息

Kanwal Fasiha, Shubrook Jay H, Younossi Zobair, Natarajan Yamini, Bugianesi Elisabetta, Rinella Mary E, Harrison Stephen A, Mantzoros Christos, Pfotenhauer Kim, Klein Samuel, Eckel Robert H, Kruger Davida, El-Serag Hashem, Cusi Kenneth

机构信息

Baylor College of Medicine, Veterans Affairs Health Services Research and Development Service, Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States of America.

Touro University California, College of Osteopathic Medicine, Vallejo, CA, United States of America.

出版信息

Metabolism. 2021 Sep;122:154822. doi: 10.1016/j.metabol.2021.154822. Epub 2021 Jul 19.

DOI:10.1016/j.metabol.2021.154822
PMID:34289945
Abstract

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are common conditions with a rising burden. Yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Further, there is no single global guiding strategy for the management of NAFLD and NASH. The American Gastroenterological Association, in collaboration with 7 professional associations, convened an international conference comprising 32 experts in gastroenterology, hepatology, endocrinology, and primary care providers from the United States, Europe, Asia, and Australia. Conference content was informed by the results of a national NASH Needs Assessment Survey. The participants reviewed and discussed published literature on global burden, screening, risk stratification, diagnosis, and management of individuals with NAFLD, including those with NASH. Participants identified promising approaches for clinical practice and prepared a comprehensive, unified strategy for primary care providers and relevant specialists encompassing the full spectrum of NAFLD/NASH care. They also identified specific high-yield targets for clinical research and called for a unified, international public health response to NAFLD and NASH.

摘要

非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)是负担日益加重的常见病症。然而,NAFLD和NASH患者的临床指南与实际治疗之间存在显著差距。此外,对于NAFLD和NASH的管理,尚无单一的全球指导策略。美国胃肠病学会与7个专业协会合作,召开了一次国际会议,参会人员包括来自美国、欧洲、亚洲和澳大利亚的32位胃肠病学、肝病学、内分泌学专家以及初级保健提供者。会议内容参考了一项全国性NASH需求评估调查的结果。与会者回顾并讨论了已发表的关于NAFLD患者(包括NASH患者)的全球负担、筛查、风险分层、诊断和管理的文献。与会者确定了有前景的临床实践方法,并为初级保健提供者和相关专家制定了一项全面、统一的策略,涵盖了NAFLD/NASH护理的各个方面。他们还确定了临床研究的特定高产目标,并呼吁对NAFLD和NASH采取统一的国际公共卫生应对措施。

相似文献

1
Preparing for the NASH epidemic: A call to action.应对非酒精性脂肪性肝炎流行:行动呼吁。
Metabolism. 2021 Sep;122:154822. doi: 10.1016/j.metabol.2021.154822. Epub 2021 Jul 19.
2
Preparing for the NASH Epidemic: A Call to Action.应对 NASH 流行:行动呼吁。
Diabetes Care. 2021 Sep;44(9):2162-2172. doi: 10.2337/dci21-0020. Epub 2021 Jul 26.
3
Preparing for the NASH epidemic: A call to action.应对 NASH 流行的准备:行动呼吁。
Obesity (Silver Spring). 2021 Sep;29(9):1401-1412. doi: 10.1002/oby.23250. Epub 2021 Aug 8.
4
Preparing for the NASH Epidemic: A Call to Action.应对 NASH 流行:行动呼吁。
Gastroenterology. 2021 Sep;161(3):1030-1042.e8. doi: 10.1053/j.gastro.2021.04.074. Epub 2021 Jul 26.
5
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.美国非酒精性脂肪性肝炎相关肝硬化的患病率:基于国家健康与营养检查调查数据的分析
Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14.
6
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.一项关于欧洲对非酒精性脂肪性肝病公共卫生应对措施的横断面研究。
J Hepatol. 2020 Jan;72(1):14-24. doi: 10.1016/j.jhep.2019.08.027. Epub 2019 Sep 10.
7
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.全球非酒精性脂肪性肝病(NASH)/非酒精性脂肪性肝病(NAFLD)患者的临床和患者报告结局:来自全球非酒精性脂肪性肝炎(NASH)/非酒精性脂肪性肝病(NAFLD)注册中心的数据。
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2296-2306.e6. doi: 10.1016/j.cgh.2021.11.004. Epub 2021 Nov 9.
8
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World.非酒精性脂肪性肝病和非酒精性脂肪性肝炎在美国和世界其他地区的流行病学。
Clin Liver Dis. 2016 May;20(2):205-14. doi: 10.1016/j.cld.2015.10.001. Epub 2015 Dec 14.
9
Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.非酒精性脂肪性肝炎(NASH)——当前的治疗建议及未来发展
Z Gastroenterol. 2019 Apr;57(4):508-517. doi: 10.1055/a-0784-8827. Epub 2019 Apr 9.
10
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.美国和欧洲非酒精性脂肪性肝病的经济和临床负担。
Hepatology. 2016 Nov;64(5):1577-1586. doi: 10.1002/hep.28785. Epub 2016 Sep 26.

引用本文的文献

1
Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: a qualitative study.从胃肠病学和肝病学专家角度看非酒精性脂肪性肝病管理中的挑战与需求:一项定性研究
BMC Gastroenterol. 2025 May 22;25(1):396. doi: 10.1186/s12876-025-03921-z.
2
Activation of Nrf2 and FXR via Natural Compounds in Liver Inflammatory Disease.天然化合物在肝脏炎症性疾病中对 Nrf2 和 FXR 的激活作用。
Int J Mol Sci. 2024 Oct 18;25(20):11213. doi: 10.3390/ijms252011213.
3
Clinical cohort of nonalcoholic fatty liver disease in a primary care setting.
基层医疗环境中非酒精性脂肪性肝病的临床队列
J Family Med Prim Care. 2024 Aug;13(8):2958-2963. doi: 10.4103/jfmpc.jfmpc_1769_23. Epub 2024 Jul 26.
4
Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017-2020.美国非酒精性脂肪性肝炎(NASH)患者与匹配的非 NASH 对照者的心血管风险,全国健康和营养调查,2017-2020 年。
PLoS One. 2024 Aug 27;19(8):e0309617. doi: 10.1371/journal.pone.0309617. eCollection 2024.
5
Interplay Between Fatty Acids, Stearoyl-Co-A Desaturase, Mechanistic Target of Rapamycin, and Yes-Associated Protein/Transcriptional Coactivator With PDZ-Binding Motif in Promoting Hepatocellular Carcinoma.脂肪酸、硬脂酰辅酶A去饱和酶、雷帕霉素作用靶点以及Yes相关蛋白/含PDZ结合基序的转录共激活因子在促进肝细胞癌中的相互作用
Gastro Hep Adv. 2022 Aug 3;2(2):232-241. doi: 10.1016/j.gastha.2022.07.017. eCollection 2023.
6
Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD but not in hyperlipidemic but otherwise metabolically healthy subjects with obesity.在 MASLD 患者中,循环总 GDF15 和 H 特异性 GDF15 水平升高,但在高脂血症但其他代谢健康的肥胖患者中则没有。
Cardiovasc Diabetol. 2024 May 18;23(1):174. doi: 10.1186/s12933-024-02264-5.
7
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know.解读非酒精性脂肪性肝病临床实践指南:临床医生需要了解的内容
Diabetes Spectr. 2024 Winter;37(1):29-38. doi: 10.2337/dsi23-0014. Epub 2024 Feb 15.
8
Saroglitazar in Non-alcoholic Fatty Liver Disease From Bench to Bedside: A Comprehensive Review and Sub-group Meta-Analysis.非酒精性脂肪性肝病中从实验室到临床的司美格鲁他扎:一项全面综述与亚组荟萃分析
Cureus. 2023 Oct 22;15(10):e47493. doi: 10.7759/cureus.47493. eCollection 2023 Oct.
9
The role of microbiome in the pathogenesis of oral-gut-liver axis between periodontitis and nonalcoholic fatty liver disease.微生物群落在牙周炎与非酒精性脂肪性肝病之间的口腔-肠道-肝脏轴发病机制中的作用。
J Dent Sci. 2023 Jul;18(3):972-975. doi: 10.1016/j.jds.2023.03.012. Epub 2023 Mar 25.
10
Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease.脂肪性肝病/非酒精性脂肪性肝病中的精准医学
J Pers Med. 2023 May 14;13(5):830. doi: 10.3390/jpm13050830.